Elanco Animal Health Inc
ELAN
Company Profile
Business description
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Contact
2500 Innovation Way
GreenfieldIN46140
USAT: +1 877 352-6261
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
9,450
Stocks News & Analysis
stocks
Ask the analyst: Are markets missing something with CSL?
I catch up with Shane Ponraj after an eventful reporting season for healthcare major CSL.
stocks
This ASX stock’s bubble has well and truly burst
Pandemic related tailwinds are a distant memory for Reece, which looks set to face more competition in Australia.
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,221.10 | 7.40 | -0.08% |
| CAC 40 | 7,709.81 | 133.23 | -1.70% |
| DAX 40 | 24,152.87 | 120.25 | -0.50% |
| Dow JONES (US) | 45,418.07 | 135.60 | 0.30% |
| FTSE 100 | 9,265.80 | 55.60 | -0.60% |
| HKSE | 25,422.61 | 102.31 | -0.40% |
| NASDAQ | 21,544.27 | 94.98 | 0.44% |
| Nikkei 225 | 42,466.84 | 72.44 | 0.17% |
| NZX 50 Index | 12,861.84 | 96.14 | -0.74% |
| S&P 500 | 6,465.94 | 26.62 | 0.41% |
| S&P/ASX 200 | 8,953.10 | 8.10 | -0.09% |
| SSE Composite Index | 3,873.48 | 5.10 | 0.13% |